Per‐and polyfluoroalkyl substance toxicity and human health review: Current state of knowledge and strategies for informing future research SE Fenton, A Ducatman, A Boobis, JC DeWitt, C Lau, C Ng, JS Smith, ... Environmental toxicology and chemistry 40 (3), 606-630, 2021 | 1419 | 2021 |
Therapeutic drugs SC Dollery Churchill Livingstone, 1997 | 1091 | 1997 |
Scientific Opinion on arsenic in food EFSA Panel on Contaminants in the Food Chain (CONTAM) Efsa Journal 7 (10), 1351, 2009 | 985* | 2009 |
Alternative (non-animal) methods for cosmetics testing: current status and future prospects—2010 S Adler, D Basketter, S Creton, O Pelkonen, J Van Benthem, V Zuang, ... Archives of toxicology 85, 367-485, 2011 | 660 | 2011 |
Methods of in vitro toxicology G Eisenbrand, B Pool-Zobel, V Baker, M Balls, BJ Blaauboer, A Boobis, ... Food and chemical toxicology 40 (2-3), 193-236, 2002 | 637 | 2002 |
Therapeutic drugs CT Dollery (No Title), 1991 | 599 | 1991 |
Evidence for genotoxicity of pesticides in pesticide applicators: a review S Bull, K Fletcher, AR Boobis, JM Battershill Mutagenesis 21 (2), 93-103, 2006 | 532 | 2006 |
Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human micro-somal protein and hepatocellularity … ZE Barter, MK Bayliss, PH Beaune, AR Boobis, DJ Carlile, RJ Edwards, ... Current drug metabolism 8 (1), 33-45, 2007 | 510 | 2007 |
Managing the challenge of chemically reactive metabolites in drug development BK Park, A Boobis, S Clarke, CEP Goldring, D Jones, JG Kenna, ... Nature Reviews Drug Discovery 10 (4), 292-306, 2011 | 509 | 2011 |
IPCS framework for analyzing the relevance of a cancer mode of action for humans AR Boobis, SM Cohen, V Dellarco, D McGregor, ME Meek, C Vickers, ... Critical reviews in toxicology 36 (10), 781-792, 2006 | 502 | 2006 |
Cytochrome P450 expression in human hepatocytes and hepatoma cell lines: molecular mechanisms that determine lower expression in cultured cells C Rodríguez-Antona, MT Donato, A Boobis, RJ Edwards, PS Watts, ... Xenobiotica 32 (6), 505-520, 2002 | 480 | 2002 |
Risk assessment of combined exposure to multiple chemicals: a WHO/IPCS framework ME Meek, AR Boobis, KM Crofton, G Heinemeyer, M Van Raaij, C Vickers Regul Toxicol Pharmacol 60 (2), S1-S14, 2011 | 436 | 2011 |
Towards microbial fermentation metabolites as markers for health benefits of prebiotics KA Verbeke, AR Boobis, A Chiodini, CA Edwards, A Franck, ... Nutrition research reviews 28 (1), 42-66, 2015 | 392 | 2015 |
Systems toxicology: from basic research to risk assessment SJ Sturla, AR Boobis, RE FitzGerald, J Hoeng, RJ Kavlock, K Schirmer, ... Chemical research in toxicology 27 (3), 314-329, 2014 | 373 | 2014 |
Cumulative risk assessment of pesticide residues in food AR Boobis, BC Ossendorp, U Banasiak, PY Hamey, I Sebestyen, ... Toxicology letters 180 (2), 137-150, 2008 | 372 | 2008 |
IPCS framework for analyzing the relevance of a noncancer mode of action for humans AR Boobis, JE Doe, B Heinrich-Hirsch, ME Meek, S Munn, M Ruchirawat, ... Critical reviews in toxicology 38 (2), 87-96, 2008 | 365 | 2008 |
Meta-analysis of studies of alcohol and breast cancer with consideration of the methodological issues J Key, S Hodgson, RZ Omar, TK Jensen, SG Thompson, AR Boobis, ... Cancer Causes & Control 17, 759-770, 2006 | 341 | 2006 |
Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man. D Sesardic, AR Boobis, BP Murray, S Murray, J Segura, R De La Torre, ... British journal of clinical pharmacology 29 (6), 651-663, 1990 | 333 | 1990 |
Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways R Bort, K Macé, A Boobis, MJ Gómez-Lechón, A Pfeifer, J Castell Biochemical pharmacology 58 (5), 787-796, 1999 | 327 | 1999 |
CYP1A2-catalyzed conversion of dietary heterocyclic amines to their proximate carcinogens is their major route of metabolism in humans AR Boobis, AM Lynch, S Murray, R de la Torre, A Solans, M Farré, ... Cancer research 54 (1), 89-94, 1994 | 324 | 1994 |